Document is current

Article History

Received: 30 September 2024

Accepted: 13 March 2025

First Online: 28 March 2025

Declarations

:

: Overall approval as well as ethical approval for this study was received from the Quality Improvement and Clinical Audit Committee at the Christie NHS Foundation Trust for the study on 22nd April 2022 (reference 3299).As this was a retrospective study, consent to participate was not applicable and not required by the Quality Improvement and Clinical Audit Committee which provided approval for the project.

: Not applicable.

: AA: None declared.NC: Financial Interests, Institutional, Invited Speaker: Roche, Taiho, AstraZeneca, RedX, Orion, Avacta, Bayer, Eisai, UCB, Starpharma, Boehringer Ingelheim, Stemline, Ergomed, LOXO Oncology, Nutide; Non-Financial Interests, Personal, Advisory Role: Roche.DMG: Financial Interests, Personal, Advisory Board, Consulting role on advisory board: Clinigen; Financial Interests, Personal, Invited Speaker: Cancer Drug Development Fund; Financial Interests, Personal, Advisory Board: McCann Health; Financial Interests, Institutional, Invited Speaker, Institutional funding from study: MSD, Codiak Biosciences, Starpharma, Faron Pharmaceuticals, Synthon, Janssen, Incyte; Financial Interests, Institutional, Research Grant: AstraZeneca.MK: Financial Interests, Personal, Advisory Board: Bayer, Roche, Janssen, Guardant Health; Financial Interests, Personal, Invited Speaker: Roche, Janssen; Financial Interests, Institutional, Expert Testimony: AstraZeneca; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Blueprint, Astex, Bayer, BerGenBio, Carrick, Immutep, Janssen, Novartis, Nurix, Nuvalent, Pyramid Biosciences, Roche, Seattle Genetics, Turning Point Therapeutics; Financial Interests, Institutional, Research Grant: Roche, Novartis; Other, Personal, Other, Travel expenses for congress: Immutep, Janssen.FT: Financial interests, Personal, Advisory Board: BMS, CytomX, F-Star, Grey Wolf Therapeutics, GSK, Immatics, Leucid, Scenic Biotech, T-Knife Therapeutics; Financial interests, Personal, Invited Speaker: Kite Gilead; Financial interests, Personal, Other, Consultancy: Guidepoint; Financial interests, Institutional, Other: iMATCH director; Financial interests, Institutional, Local PI: Achilles ltd, Adaptimmune, Agalimmune Ltd, BMS, Crescendo, CytomX, GenMab, Immunocore, Incyte, Janssen, Novalgen, Novartis, Nucana, Oxford Vacmedix Ltd, Pfizer, RS Oncology LLC; Financial interests, Institutional, Coordinating PI: ADCT Therapeutics, Chugai, GSK, Instil Bio, Kymab Ltd/Sanofi, Roche; Financial interests, Institutional, Research Grant: GSK, Novartis, Autolus, Gilead; Non-financial interests, Institutional, Coordinating PI: T-Knife Therapeutics, AstraZeneca; Non-financial interests, Personal, Leadership role: Chair of the Independent Steering Committee for NIHR Blood & Transplant Research Unit, ESMO Congress 2024 Experimental Immunotherapy Track Chair, MRC Advanced Therapies Task Group, CRUK New Agents Committee Member, ESMO TAT conference scientific advisory board 2025, Sarcoma UK, Target Ovarian Cancer.LC: Financial Interests, Personal, Other, Consultancy: Bicycle Therapeutics, Boehringer Ingelheim, Athenex; Financial Interests, Personal, Full or part-time Employment, Medical Advisor: Cancer Research UK Centre for Drug Development; Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, Bicycle Therapeutics, Cellcentric, Eli Lilly, Athenex, Lupin Limited, Repare Therapeutics, Cytomx therapeutics, EMD Serono/Merck KGaA, Sierra Oncology.